Basic Information
| LncRNA/CircRNA Name | FALEC |
| Synonyms | NA |
| Region | GRCh38_1:150515757-150518032 |
| Ensemble | ENSG00000228126 |
| Refseq | NR_051960 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | Human endometrial cancer cell lines (KLE, HEC-1-A, Ishikawa and RL95-2), normal endocervical cell line (End1/E6E7), endometrial cancer tissue, corresponding paracancerous normal tissue, endometrial cancer tissue, corresponding paracancerous normal tissue |
| Expression Pattern | up-regulated |
| Function Description | FALEC expression was increased in endometrial cancer tissue samples and cell lines compared with corresponding paracancerous normal tissue samples and cell line, respectively. Furthermore, we investigated the clinical significance of FALEC in endometrial cancer patients, and found endometrial cancer patients with advanced clinical stage or large tumor size had higher levels of FALEC expression than those with early clinical stage or small tumor size. The in vitro studies showed silencing of FALEC expression inhibited cell proliferation and arrested cell cycle at G0/G1. I |
| Pubmed ID | 31387003 |
| Year | 2019 |
| Title | FALEC exerts oncogenic properties to regulate cell proliferation and cellcycle in endometrial cancer |
External Links
| Links for FALEC | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |